FindTrial
Sign In

Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)

Optimization of treatment and diagnosis plan for critically ill patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029804
Enrollment
Unknown
Registered
2020-02-14
Start date
2020-02-12
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:NA

Sponsors

Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who meet the requirements of the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Trial Version 4)" which issued by the General Office of the National Health Commission. 2. ECMO-treated patients with severe hypoxic respiratory failure.

Exclusion criteria

Exclusion criteria: 1. Age> 75 years. 2. After CPR. 3. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).

Design outcomes

Primary

MeasureTime frame
Inpatient mortality;—

Secondary

MeasureTime frame
ICU hospital stay;Total hospital stay;ICU fatality rate;—

Countries

China

Contacts

Public ContactWu Wenjuan

Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)

1346801465@qq.com+86 13397192695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026